Details of the Drug

General Information of Drug (ID: DMKVWGE)

Drug Name
Dexbrompheniramine
Synonyms
Dexbromfeniramina; Dexbrompheniraminum; Ilvin; Parabromodylamine; D-Brompheniramine; Dexbromfeniramina [INN-Spanish]; Dexbrompheniramine [INN:BAN]; Dexbrompheniraminum [INN-Latin]; N,N-Dimethyl-(3-(4-bromphenyl)-3-(2-pyridyl)propyl)amin; (3-p-Bromphenyl-3-pyrid-2'-ylpropyl)dimethylamin; (3S)-3-(4-bromophenyl)-N,N-dimethyl-3-(pyridin-2-yl)propan-1-amine; (3S)-3-(4-bromophenyl)-N,N-dimethyl-3-pyridin-2-ylpropan-1-amine; (S)-(+)-brompheniramine; (S)-brompheniramine
Indication
Disease Entry ICD 11 Status REF
Allergic rhinitis CA08.0 Approved [1]
Hay fever CA08.00 Approved [2]
Seasonal allergic rhinitis CA08.01 Approved [1]
Urticaria EB00-EB05 Approved [1]
Vasomotor/allergic rhinitis CA08 Approved [1]
Pruritus EC90 Investigative [1]
⏷ Show the Full List of Indication(s)
Therapeutic Class
Antihistamines
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 319.24
Logarithm of the Partition Coefficient (xlogp) 3.5
Rotatable Bond Count (rotbonds) 5
Hydrogen Bond Donor Count (hbonddonor) 0
Hydrogen Bond Acceptor Count (hbondacc) 2
ADMET Property
Absorption
The drug is well absorbed from the gastrointestinal tract []
Half-life
The concentration or amount of drug in body reduced by one-half in 25 hours [3]
Metabolism
The drug is metabolized via the hepatic []
Chemical Identifiers
Formula
C16H19BrN2
IUPAC Name
(3S)-3-(4-bromophenyl)-N,N-dimethyl-3-pyridin-2-ylpropan-1-amine
Canonical SMILES
CN(C)CC[C@@H](C1=CC=C(C=C1)Br)C2=CC=CC=N2
InChI
InChI=1S/C16H19BrN2/c1-19(2)12-10-15(16-5-3-4-11-18-16)13-6-8-14(17)9-7-13/h3-9,11,15H,10,12H2,1-2H3/t15-/m0/s1
InChIKey
ZDIGNSYAACHWNL-HNNXBMFYSA-N
Cross-matching ID
PubChem CID
16960
ChEBI ID
CHEBI:59269
CAS Number
132-21-8
DrugBank ID
DB00405
TTD ID
D02WIW
ACDINA ID
D00186
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Histamine H1 receptor (H1R) TTTIBOJ HRH1_HUMAN Antagonist [4]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Potassium voltage-gated channel subfamily H member 2 (KCNH2) OTZX881H KCNH2_HUMAN Gene/Protein Processing [5]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Allergic rhinitis
ICD Disease Classification CA08.0
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Histamine H1 receptor (H1R) DTT HRH1 6.74E-01 0.13 0.43
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Dexbrompheniramine
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Chlorpheniramine DM5URA2 Moderate Additive anticholinergic effects by the combination of Dexbrompheniramine and Chlorpheniramine. Vasomotor/allergic rhinitis [CA08] [6]
Triprolidine DM7SWIA Moderate Additive anticholinergic effects by the combination of Dexbrompheniramine and Triprolidine. Vasomotor/allergic rhinitis [CA08] [6]
Methdilazine DMAUHQX Moderate Additive anticholinergic effects by the combination of Dexbrompheniramine and Methdilazine. Vasomotor/allergic rhinitis [CA08] [6]
Carbinoxamine DMCT31R Moderate Additive anticholinergic effects by the combination of Dexbrompheniramine and Carbinoxamine. Vasomotor/allergic rhinitis [CA08] [6]
Trimeprazine DMEMV9D Moderate Additive anticholinergic effects by the combination of Dexbrompheniramine and Trimeprazine. Vasomotor/allergic rhinitis [CA08] [7]
Brompheniramine DMFOVSD Moderate Additive anticholinergic effects by the combination of Dexbrompheniramine and Brompheniramine. Vasomotor/allergic rhinitis [CA08] [6]
Acrivastine DMTIGA0 Moderate Additive anticholinergic effects by the combination of Dexbrompheniramine and Acrivastine. Vasomotor/allergic rhinitis [CA08] [6]
Azatadine DMZ80SB Moderate Additive anticholinergic effects by the combination of Dexbrompheniramine and Azatadine. Vasomotor/allergic rhinitis [CA08] [6]
⏷ Show the Full List of 8 DDI Information of This Drug
Coadministration of a Drug Treating the Disease Different from Dexbrompheniramine (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Scopolamine DMOM8AL Moderate Additive anticholinergic effects by the combination of Dexbrompheniramine and Scopolamine. Addictive disorder [6C50-6C5Z] [6]
Mepyramine DMB4SFH Moderate Additive anticholinergic effects by the combination of Dexbrompheniramine and Mepyramine. Allergic/hypersensitivity disorder [4A80-4A8Z] [7]
Phenyltoloxamine DMKAEQW Moderate Additive anticholinergic effects by the combination of Dexbrompheniramine and Phenyltoloxamine. Allergic/hypersensitivity disorder [4A80-4A8Z] [7]
Tripelennamine DMZBU15 Moderate Additive anticholinergic effects by the combination of Dexbrompheniramine and Tripelennamine. Allergic/hypersensitivity disorder [4A80-4A8Z] [6]
Memantine DMD9WSC Moderate Additive anticholinergic effects by the combination of Dexbrompheniramine and Memantine. Alzheimer disease [8A20] [6]
Galantamine DMEO794 Moderate Antagonize the effect of Dexbrompheniramine when combined with Galantamine. Alzheimer disease [8A20] [8]
Rivastigmine DMG629M Moderate Antagonize the effect of Dexbrompheniramine when combined with Rivastigmine. Alzheimer disease [8A20] [8]
Donepezil DMIYG7Z Moderate Antagonize the effect of Dexbrompheniramine when combined with Donepezil. Alzheimer disease [8A20] [8]
Hydroxyzine DMF8Y74 Moderate Additive anticholinergic effects by the combination of Dexbrompheniramine and Hydroxyzine. Anxiety disorder [6B00-6B0Z] [6]
Promazine DMZAL7W Moderate Additive anticholinergic effects by the combination of Dexbrompheniramine and Promazine. Appearance/behaviour symptom [MB23] [6]
Desipramine DMT2FDC Moderate Additive anticholinergic effects by the combination of Dexbrompheniramine and Desipramine. Attention deficit hyperactivity disorder [6A05] [6]
Linezolid DMGFPU2 Moderate Additive CNS depression effects by the combination of Dexbrompheniramine and Linezolid. Bacterial infection [1A00-1C4Z] [9]
Cariprazine DMJYDVK Moderate Additive anticholinergic effects by the combination of Dexbrompheniramine and Cariprazine. Bipolar disorder [6A60] [6]
Loperamide DMOJZQ9 Moderate Additive antimotility effects by the combination of Dexbrompheniramine and Loperamide. Bowel habit change [ME05] [10]
Acetylcholine DMDF79Z Moderate Antagonize the effect of Dexbrompheniramine when combined with Acetylcholine. Cataract [9B10] [11]
Umeclidinium DM4E8O9 Moderate Additive anticholinergic effects by the combination of Dexbrompheniramine and Umeclidinium. Chronic obstructive pulmonary disease [CA22] [12]
Tiotropium DMFDC0Q Moderate Additive anticholinergic effects by the combination of Dexbrompheniramine and Tiotropium. Chronic obstructive pulmonary disease [CA22] [12]
Revefenacin DMMP5SI Moderate Additive anticholinergic effects by the combination of Dexbrompheniramine and Revefenacin. Chronic obstructive pulmonary disease [CA22] [12]
Olopatadine DMKMWQG Moderate Additive CNS depression effects by the combination of Dexbrompheniramine and Olopatadine. Conjunctiva disorder [9A60] [13]
Ethanol DMDRQZU Moderate Additive CNS depression effects by the combination of Dexbrompheniramine and Ethanol. Cystitis [GC00] [13]
Trimipramine DM1SC8M Moderate Additive anticholinergic effects by the combination of Dexbrompheniramine and Trimipramine. Depression [6A70-6A7Z] [6]
Cyclobenzaprine DM1YBRM Moderate Additive anticholinergic effects by the combination of Dexbrompheniramine and Cyclobenzaprine. Depression [6A70-6A7Z] [6]
Imipramine DM2NUH3 Moderate Additive anticholinergic effects by the combination of Dexbrompheniramine and Imipramine. Depression [6A70-6A7Z] [6]
Nortriptyline DM4KDYJ Moderate Additive anticholinergic effects by the combination of Dexbrompheniramine and Nortriptyline. Depression [6A70-6A7Z] [6]
Isocarboxazid DMAF1NB Moderate Additive CNS depression effects by the combination of Dexbrompheniramine and Isocarboxazid. Depression [6A70-6A7Z] [9]
Tranylcypromine DMGB5RE Moderate Additive CNS depression effects by the combination of Dexbrompheniramine and Tranylcypromine. Depression [6A70-6A7Z] [9]
OPC-34712 DMHG57U Moderate Additive anticholinergic effects by the combination of Dexbrompheniramine and OPC-34712. Depression [6A70-6A7Z] [6]
Phenelzine DMHIDUE Moderate Additive CNS depression effects by the combination of Dexbrompheniramine and Phenelzine. Depression [6A70-6A7Z] [9]
Clomipramine DMINRKW Moderate Additive anticholinergic effects by the combination of Dexbrompheniramine and Clomipramine. Depression [6A70-6A7Z] [6]
Amoxapine DMKITQE Moderate Additive anticholinergic effects by the combination of Dexbrompheniramine and Amoxapine. Depression [6A70-6A7Z] [6]
Doxepin DMPI98T Moderate Additive anticholinergic effects by the combination of Dexbrompheniramine and Doxepin. Depression [6A70-6A7Z] [6]
Maprotiline DMPWB7T Moderate Additive anticholinergic effects by the combination of Dexbrompheniramine and Maprotiline. Depression [6A70-6A7Z] [6]
Esketamine DMVU687 Moderate Additive CNS depression effects by the combination of Dexbrompheniramine and Esketamine. Depression [6A70-6A7Z] [14]
Hyoscyamine DM804UR Moderate Additive anticholinergic effects by the combination of Dexbrompheniramine and Hyoscyamine. Digestive system disease [DE2Z] [6]
Mepenzolate DM8YU2F Moderate Additive anticholinergic effects by the combination of Dexbrompheniramine and Mepenzolate. Digestive system disease [DE2Z] [6]
Oxybutynine DMJPBAX Moderate Additive anticholinergic effects by the combination of Dexbrompheniramine and Oxybutynine. Discovery agent [N.A.] [6]
Meclizine DMS7T13 Moderate Additive anticholinergic effects by the combination of Dexbrompheniramine and Meclizine. Dizziness and giddiness [MB48] [6]
Zonisamide DM0DTF7 Major Increased risk of hyperpyrexia by the combination of Dexbrompheniramine and Zonisamide. Epilepsy/seizure [8A61-8A6Z] [15]
Diphenhydramine DMKQTBA Moderate Additive anticholinergic effects by the combination of Dexbrompheniramine and Diphenhydramine. Episodic vestibular syndrome [AB31] [6]
Solifenacin DMG592Q Moderate Additive anticholinergic effects by the combination of Dexbrompheniramine and Solifenacin. Functional bladder disorder [GC50] [6]
Tolterodine DMSHPW8 Moderate Additive anticholinergic effects by the combination of Dexbrompheniramine and Tolterodine. Functional bladder disorder [GC50] [6]
Darifenacin DMWXLYZ Moderate Additive anticholinergic effects by the combination of Dexbrompheniramine and Darifenacin. Functional bladder disorder [GC50] [6]
Propantheline DM2EN6G Moderate Additive anticholinergic effects by the combination of Dexbrompheniramine and Propantheline. Gastric ulcer [DA60] [6]
Isoflurophate DMBSK7X Moderate Antagonize the effect of Dexbrompheniramine when combined with Isoflurophate. Glaucoma [9C61] [11]
Brimonidine DMQLT4N Moderate Additive CNS depression effects by the combination of Dexbrompheniramine and Brimonidine. Glaucoma [9C61] [16]
Pilocarpine DMV9ADG Moderate Antagonize the effect of Dexbrompheniramine when combined with Pilocarpine. Glaucoma [9C61] [11]
Procarbazine DMIK367 Moderate Additive CNS depression effects by the combination of Dexbrompheniramine and Procarbazine. Hodgkin lymphoma [2B30] [9]
Belladonna DM2RBWK Moderate Additive anticholinergic effects by the combination of Dexbrompheniramine and Belladonna. Infectious gastroenteritis/colitis [1A40] [6]
Amantadine DMS3YE9 Moderate Additive anticholinergic effects by the combination of Dexbrompheniramine and Amantadine. Influenza [1E30-1E32] [17]
ITI-007 DMUQ1DO Moderate Additive anticholinergic effects by the combination of Dexbrompheniramine and ITI-007. Insomnia [7A00-7A0Z] [6]
Clidinium DMUMQZ0 Moderate Additive anticholinergic effects by the combination of Dexbrompheniramine and Clidinium. Irritable bowel syndrome [DD91] [6]
Dicyclomine DMZSDGX Moderate Additive anticholinergic effects by the combination of Dexbrompheniramine and Dicyclomine. Irritable bowel syndrome [DD91] [6]
Physostigmine DM2N0TO Moderate Antagonize the effect of Dexbrompheniramine when combined with Physostigmine. Lips/oral mucosa miscellaneous disorder [DA02] [8]
Allopregnanolone DMNLHAC Moderate Additive CNS depression effects by the combination of Dexbrompheniramine and Allopregnanolone. Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z] [18]
Lasmiditan DMXLVDT Moderate Additive CNS depression effects by the combination of Dexbrompheniramine and Lasmiditan. Migraine [8A80] [19]
Flibanserin DM70DTN Moderate Additive CNS depression effects by the combination of Dexbrompheniramine and Flibanserin. Mood disorder [6A60-6E23] [20]
Thalidomide DM70BU5 Moderate Additive CNS depression effects by the combination of Dexbrompheniramine and Thalidomide. Multiple myeloma [2A83] [21]
Phenindamine DMDTC7R Moderate Additive anticholinergic effects by the combination of Dexbrompheniramine and Phenindamine. Nasopharyngitis [CA00] [6]
Dimenhydrinate DM264B3 Moderate Additive anticholinergic effects by the combination of Dexbrompheniramine and Dimenhydrinate. Nausea/vomiting [MD90] [6]
Prochlorperazine DM53SRA Moderate Additive anticholinergic effects by the combination of Dexbrompheniramine and Prochlorperazine. Nausea/vomiting [MD90] [6]
Promethazine DM6I5GR Moderate Additive anticholinergic effects by the combination of Dexbrompheniramine and Promethazine. Nausea/vomiting [MD90] [6]
Cyclizine DM9G7BS Moderate Additive anticholinergic effects by the combination of Dexbrompheniramine and Cyclizine. Nausea/vomiting [MD90] [6]
Apraclonidine DMO4PVE Moderate Additive CNS depression effects by the combination of Dexbrompheniramine and Apraclonidine. Optic nerve disorder [9C40] [16]
Dextropropoxyphene DM23HCX Major Additive CNS depression effects by the combination of Dexbrompheniramine and Dextropropoxyphene. Pain [MG30-MG3Z] [22]
Flavoxate DMKV4NL Moderate Additive anticholinergic effects by the combination of Dexbrompheniramine and Flavoxate. Pain [MG30-MG3Z] [6]
Biperiden DME78OA Moderate Additive anticholinergic effects by the combination of Dexbrompheniramine and Biperiden. Parkinsonism [8A00] [6]
Orphenadrine DMW542E Moderate Additive anticholinergic effects by the combination of Dexbrompheniramine and Orphenadrine. Parkinsonism [8A00] [6]
Methylscopolamine DM5VWOB Moderate Additive anticholinergic effects by the combination of Dexbrompheniramine and Methylscopolamine. Peptic ulcer [DA61] [6]
Levomepromazine DMIKFEL Moderate Additive anticholinergic effects by the combination of Dexbrompheniramine and Levomepromazine. Psychotic disorder [6A20-6A25] [6]
Fluphenazine DMIT8LX Moderate Additive anticholinergic effects by the combination of Dexbrompheniramine and Fluphenazine. Psychotic disorder [6A20-6A25] [6]
Triflupromazine DMKFQJP Moderate Additive anticholinergic effects by the combination of Dexbrompheniramine and Triflupromazine. Psychotic disorder [6A20-6A25] [6]
Cyproheptadine DM92AH3 Moderate Additive anticholinergic effects by the combination of Dexbrompheniramine and Cyproheptadine. Rheumatoid arthritis [FA20] [6]
Quetiapine DM1N62C Moderate Additive anticholinergic effects by the combination of Dexbrompheniramine and Quetiapine. Schizophrenia [6A20] [6]
Mesoridazine DM2ZGAN Moderate Additive anticholinergic effects by the combination of Dexbrompheniramine and Mesoridazine. Schizophrenia [6A20] [6]
Thioridazine DM35M8J Moderate Additive anticholinergic effects by the combination of Dexbrompheniramine and Thioridazine. Schizophrenia [6A20] [6]
Aripiprazole DM3NUMH Moderate Additive anticholinergic effects by the combination of Dexbrompheniramine and Aripiprazole. Schizophrenia [6A20] [6]
Iloperidone DM6AUFY Moderate Additive anticholinergic effects by the combination of Dexbrompheniramine and Iloperidone. Schizophrenia [6A20] [6]
Paliperidone DM7NPJS Moderate Additive anticholinergic effects by the combination of Dexbrompheniramine and Paliperidone. Schizophrenia [6A20] [6]
Loxapine DM8AI9U Moderate Additive anticholinergic effects by the combination of Dexbrompheniramine and Loxapine. Schizophrenia [6A20] [6]
Haloperidol DM96SE0 Moderate Additive anticholinergic effects by the combination of Dexbrompheniramine and Haloperidol. Schizophrenia [6A20] [6]
Perphenazine DMA4MRX Moderate Additive anticholinergic effects by the combination of Dexbrompheniramine and Perphenazine. Schizophrenia [6A20] [6]
Molindone DMAH70G Moderate Additive anticholinergic effects by the combination of Dexbrompheniramine and Molindone. Schizophrenia [6A20] [6]
Chlorpromazine DMBGZI3 Moderate Additive anticholinergic effects by the combination of Dexbrompheniramine and Chlorpromazine. Schizophrenia [6A20] [6]
Thiothixene DMDINC4 Moderate Additive anticholinergic effects by the combination of Dexbrompheniramine and Thiothixene. Schizophrenia [6A20] [6]
Trifluoperazine DMKBYWI Moderate Additive anticholinergic effects by the combination of Dexbrompheniramine and Trifluoperazine. Schizophrenia [6A20] [6]
Risperidone DMN6DXL Moderate Additive anticholinergic effects by the combination of Dexbrompheniramine and Risperidone. Schizophrenia [6A20] [6]
Asenapine DMSQZE2 Moderate Additive anticholinergic effects by the combination of Dexbrompheniramine and Asenapine. Schizophrenia [6A20] [6]
Pimozide DMW83TP Moderate Additive anticholinergic effects by the combination of Dexbrompheniramine and Pimozide. Schizophrenia [6A20] [6]
Tizanidine DMR2IQ4 Moderate Additive CNS depression effects by the combination of Dexbrompheniramine and Tizanidine. Tonus and reflex abnormality [MB47] [23]
Atropine DMEN6X7 Moderate Additive anticholinergic effects by the combination of Dexbrompheniramine and Atropine. Unspecific substance harmful effect [NE6Z] [6]
⏷ Show the Full List of 90 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Mannitol E00103 6251 Diluent; Flavoring agent; Lyophilization aid; Plasticizing agent; Tonicity agent
Stearic acid E00079 5281 Emulsifying agent; Solubilizing agent; Viscosity-controlling agent; lubricant
Sucralose E00370 71485 Flavoring agent
Brushite E00392 104805 Diluent
Carmellose sodium E00625 Not Available Disintegrant
Magnesium stearate E00208 11177 lubricant
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Xylitol E00136 6912 Coating agent; Diluent; Emollient; Flavoring agent; Humectant
⏷ Show the Full List of 8 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Dexbrompheniramine 1 mg tablet 1 mg Chewable Tablet Oral
Dexbrompheniramine 2 mg tablet 2 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 Dexbrompheniramine FDA Label
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7588).
3 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
4 H2 histaminergic control of inhibition of eating induced by intragastric NaCl in rats. Physiol Behav. 1998 Aug;65(1):105-13.
5 Why are most phospholipidosis inducers also hERG blockers?. Arch Toxicol. 2017 Dec;91(12):3885-3895. doi: 10.1007/s00204-017-1995-9. Epub 2017 May 27.
6 Cohen MA, Alfonso CA, Mosquera M. Development of urinary retention during treatment with clozapine and meclizine [published correction appears in Am J Psychiatry 1994 Jun;151(6):952]. Am J Psychiatry. 1994;151(4):619-620. [PMID: 8147469]
7 Kulik AV, Wilbur R "Delirium and stereotypy from anticholinergic antiparkinson drugs." Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82. [PMID: 7202232]
8 Beers MH, Ouslander JG, Rollingher I, Reuben DB, Brooks J, Beck JC "Explicit criteria for determining inappropriate medication use in nursing home residents." Arch Intern Med 151 (1991): 1825-32. [PMID: 1888249]
9 Canadian Pharmacists Association.
10 Eronen M, Putkonen H, Hallikainen T, Vartiainen H "Lethal gastroenteritis associated with clozapine and loperamide." Am J Psychiatry 160 (2003): 2242-2243. [PMID: 14638602]
11 Multum Information Services, Inc. Expert Review Panel.
12 Cole JM, Sheehan AH, Jordan JK "Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease." Ann Pharmacother 46 (2012): 1717-21. [PMID: 23170031]
13 Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002]
14 Cerner Multum, Inc. "Australian Product Information.".
15 Product Information. Zonegran (zonisamide) Elan Pharmaceuticals, S. San Francisco, CA.
16 Product Information. Alphagan (brimonidine ophthalmic). Allergan Inc, Irvine, CA.
17 Postma JU, van Tilburg W "Visual hallucinations and delirium during treatment with amantadine (Symmetrel)." J Am Geriatr Soc 23 (1975): 212-5. [PMID: 123540]
18 Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
19 Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
20 Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
21 Product Information. Thalomid (thalidomide). Celgene Corporation, Warren, NJ.
22 Hansen BS, Dam M, Brandt J, et al "Influence of dextropropoxyphene on steady state serum levels and protein binding of three anti-epileptic drugs in man." Acta Neurol Scand 61 (1980): 357-67. [PMID: 6998251]
23 Product Information. Zanaflex (tizanidine). Acorda Therapeutics, Hawthorne, NY.